Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $30.17M
• Dividend Yield: N/A
• Average Volume (3M): 126.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -100.00%
• EPS Growth: -26.30%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 40,830,353
• 10 Day Avg. Volume: 91,233
• 30 Day Avg. Volume: 126,186
• PEG Ratio: 0.04
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 3.18
• P/FCF Ratio: -1.60
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: $4.00
• Price Target Upside: 191.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.55
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.65 ▼(-52.77% Downside)

Barinthus Biotherapeutics faces significant financial and technical challenges, with ongoing losses and bearish market momentum. While the AVALON trial progress is promising, it does not offset the immediate financial and valuation concerns.

Positive Factors

Clinical Trial Progress

The positive results from the Phase 1 trial of VTP-1000 indicate potential for successful treatment development, enhancing Barinthus' position in addressing celiac disease, a significant unmet medical need.

Merger with Clywedog Therapeutics

The merger with Clywedog Therapeutics will expand Barinthus' product pipeline and market reach, potentially increasing revenue streams and strengthening its competitive position in the biotechnology sector.

Strong Equity Position

A strong equity position provides financial stability and flexibility, enabling Barinthus to invest in R&D and strategic initiatives without excessive reliance on debt.

Negative Factors

Ongoing Financial Losses

Persistent financial losses and negative cash flows could hinder Barinthus' ability to sustain operations and invest in growth opportunities, posing a risk to long-term viability.

Negative Cash Flows

Negative cash flows suggest liquidity challenges, which may limit Barinthus' capacity to fund ongoing operations and future projects, impacting its growth prospects.

Unprofitability

Continued unprofitability reflects challenges in achieving cost efficiency and revenue growth, which could affect Barinthus' ability to attract investment and sustain its business model.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue through multiple key streams, primarily from the sale of its biotherapeutic products, which are developed for specific medical conditions. The company also engages in collaborative partnerships with larger pharmaceutical firms, which may involve licensing agreements, co-development deals, and research funding. Additionally, BRNS may receive milestone payments and royalties based on the successful advancement of its products through various stages of clinical development and eventual commercialization. Grants and government funding for research initiatives further supplement the company's earnings, enabling it to innovate and expand its product pipeline.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics is experiencing financial challenges with ongoing losses and negative cash flows, despite improvements in revenue and gross profit margins. The balance sheet is stable, but the company needs to achieve profitability and improve cash flow for long-term sustainability.

Income Statement

Barinthus Biotherapeutics has shown significant volatility in its revenue and profitability. The revenue growth from 2023 to 2024 was substantial, but the company remains unprofitable with negative net income and EBIT margins. The gross profit margin improved in 2024, indicating better cost management, but the overall financial health is hindered by persistent losses.

Balance Sheet

The company's balance sheet reflects a strong equity position with a high equity ratio, indicating stability. However, the debt-to-equity ratio is relatively low, suggesting manageable leverage. The decline in stockholders' equity over the years is a concern, but the reduction in total liabilities is a positive sign.

Cash Flow

Cash flow analysis reveals challenges with negative operating and free cash flows, indicating potential liquidity issues. The free cash flow has improved slightly from 2023 to 2024, but the company continues to burn cash, which could be a risk if not addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	0.00	14.97M	802.00K	44.70M	268.00K	-9.57M
EBITDA	-69.35M	-55.37M	-71.06M	5.19M	-47.87M	-16.56M
Net Income	-75.88M	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	109.20M	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	74.27M	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	11.57M	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	24.64M	30.19M	27.51M	27.00M	28.15M	53.81M
Stockholders Equity	84.47M	130.03M	186.78M	242.90M	252.13M	-3.54M
Cash Flow
Free Cash Flow	-30.97M	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-30.65M	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	136.00K	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	839.00K	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.98, and above the 200-day MA of 1.05, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of 54.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	41 Neutral	$30.17M	―	-62.30%	―	-100.00%	-26.30%
GDTC	41 Neutral	$16.54M	-5.87	-42.29%	―	―	-21.99%
BOLD	40 Underperform	$27.31M	-0.44	-44.88%	―	―	-0.50%
ALGS	40 Underperform	$65.72M	-0.54	-141.82%	―	-55.88%	6.14%
ALXO	39 Underperform	$78.62M	-0.72	-118.95%	―	―	31.98%
CLGN	38 Underperform	$19.33M	-1.49	-92.74%	―	280.77%	32.82%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Updates on AVALON Trial Progress

On December 10, 2025, Barinthus Biotherapeutics announced an update on its Phase 1 AVALON clinical trial for VTP-1000, an antigen-specific immunotherapy for celiac disease. The single ascending dose portion of the trial showed that VTP-1000 was well-tolerated with no serious adverse events and demonstrated a dose-dependent pharmacological effect. The ongoing multiple ascending dose portion, which includes a gluten challenge, is expected to provide further insights in the second half of 2026. This development marks a significant step in addressing the unmet needs in celiac disease treatment, potentially positioning Barinthus Bio as a leader in immune tolerance therapies.

Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics

On September 29, 2025, Barinthus Biotherapeutics and Clywedog Therapeutics entered into a merger agreement to form a combined entity named Clywedog Therapeutics, Inc. The merger, expected to close in the first half of 2026, will create a company with a diversified pipeline targeting metabolic and autoimmune diseases, including Type 1 and Type 2 diabetes and celiac disease. The transaction will result in Clywedog stockholders owning approximately 66% and Barinthus shareholders owning about 34% of the new company. The combined company will be supported by existing cash and additional investments from OrbiMed and Torrey Pines Investment LLC, and is expected to trade on NASDAQ under the symbol ‘CLYD’.